Finding Better Treatments and a Cure for Recurrent Prostate Cancer: Winter 2004
Progress Report Prostate Cancer Foundation Releases Its First Annual Report to the Nation on Prostate Cancer
n addition to being the world’s leading source of philanthropic support for prostate cancer research, the Prostate Cancer Foundation (PCF) is also one of the leading sources of information about progress toward better treatments and a cure for recurrent prostate cancer and a leading force in accelerating that progress.
On September 22, the Prostate Cancer Foundation introduced a new publication designed to increase the base of knowledge about prostate cancer: The Report to the Nation on Prostate Cancer. The Report is designed to increase knowledge among physicians about leading approaches to the treatment of prostate cancer. Supported by the PCF’s Pharmaceutical Industry Roundtable, the Report provides a comprehensive overview of the stateof-the-art in the diagnosis, treatment and prevention of prostate cancer and sets a clear research agenda for the future. With authors from a wide array of specialties, the Report supports the concept of a multidisciplinary approach to the management of prostate cancer. The PCF intends the Report to be used by all those involved in the care of prostate cancer patients—including urologists, medical oncologists and radiation oncologists—
to gain a clearer understanding of how to work together to provide prostate cancer patients with optimal care. The Report also features important “calls to action” for prostate cancer researchers to address unanswered scientific questions and for healthcare providers to focus on important issues related to disease management. Two world-renowned cancer researchers served as executive editors: Peter R. Carroll, M.D., professor and chair of the Department of Urology at University of California at San Francisco, and William G. Nelson, M.D., Ph.D., professor, Departments of Oncology, Urology, Pharmacology, Medicine and Pathology at The Johns Hopkins University. Following an introduction by the executive editors, the Report is comprised of nine chapters written by 22 prostate cancer thought leaders. The chapters are:
• Detection, Diagnosis and Prognosis of Prostate Cancer
• Local Treatment of Prostate Cancer • Androgen Deprivation Therapy for Prostate Cancer
• Management of Bone Metastases in Patients with Prostate Cancer
• Chemotherapeutic Options in Patients with Prostate Cancer
• Emerging Therapies for Prostate Cancer • Management of Side Effects in Prostate Cancer Therapy
• Nutrition and Prevention Strategies for Prostate Cancer
• Therapeutic Strategies for Patients with a Rising PSA: A Case-Based Approach Although the Report is primarily targeted to physicians, well-informed patients and caregivers may find the Report interesting and valuable as well. The Report is available online at www.prostatecancerfoundation.org and is being distributed in print to more than 20,000 physicians who treat patients with prostate cancer. Following a media launch at the New York Academy of Sciences, a Continuing Medical Education (CME)-certified live symposium was held, with more than 120 tristate area physicians in attendance. An additional 300 physicians participated via a live webcast on Medscape.com (the webcast will remain available at Medscape.com for one year), and in the first week alone, more than 15,000 healthcare providers viewed the Report chapters on the Medscape site. Each of the nine chapters of the Report are also available as a CME activity on Medscape.com/prostatecancer. The Report has already generated significant media coverage from Time magazine, USA Today, NBC News, CBS News, the Washington Times, CNN.com, BusinessWeek Online and Health News Daily, among others.
Peter T. Scardino, M.D., chair of the Department of Urology and head of the prostate cancer program at Memorial Sloan-Kettering Cancer Center (left); Daniel P. Petrylak, M.D., associate professor of medicine at Columbia University College of Physicians & Surgeons (center); and Peter R. Carroll, M.D., professor and chair, UCSF Department of Urology (right), answer questions at a media briefing regarding the PCF’s Report to the Nation on Prostate Cancer held at the New York Academy of Sciences on September 22, 2004.
PCF-Funded Scientist Aaron Ciechanover Awarded Nobel Prize
The PCF gratefully acknowledges the support of Abbott Laboratories, Aventis, Novartis and Sanofi-Synthelabo, the founding members of the PCF’s Pharmaceutical Industry Roundtable, which supported this initiative and helped to defray the costs of producing the Report. The content of the Report was developed entirely by the Report’s authors with no editorial input from the members of the Roundtable in any manner.
The Prostate Cancer Foundation is pleased to honor Aaron Ciechanover, M.D., winner of the 2004 Nobel Prize in Chemistry and a recipient of multiple research grants from the Prostate Cancer Foundation. The PCF has provided Dr. Ciechanover with research grants each year since 2000 to investigate the application of his research to the development of new therapies for prostate cancer. Dr. Ciechanover has reported on these investigations at several of the PCF’s annual Scientific Retreats, including the 2004 Retreat held in October. The Nobel Foundation recognized Dr. Ciechanover’s work in illuminating the significance of the cellular machine called the proteasome, which regulates the destruction of unneeded cell proteins. The proteasome is the target of the drug Velcade, which is approved for use in treating multiple myeloma and is being tested for use in treating prostate cancer. The PCF has also provided crucial funding to support the clinical development of Velcade. “The Prostate Cancer Foundation salutes Dr. Aaron Ciechanover and congratulates him for winning the Nobel Prize in Chemistry. His discovery of the critical importance of the proteasome is crucial to the development of new therapies for prostate cancer,” said Leslie D. Michelson, vice chairman and CEO of the Prostate Cancer Foundation. “The PCF funded Dr. Ciechanover through its Israel Initiative, which is part of our worldwide effort to harness the talents of the best and brightest in the fight for better treatments and a cure for recurrent prostate cancer,” he added.
Inside This Issue
From the CEO 2 Board News 2 Science Update 3 Lifestyle 4 Recipe 5 News 6 – 7 Events 7 Calendar 8 Leadership 8
From the CEO
s part of our ongoing program to keep you informed about our progress, we want to tell you
about some important developments in our quest to find better treatments and a cure for recurrent prostate cancer. In short, this has been one of the best periods ever for scientific accomplishments, fund-raising and visibility for this cause. Here are some highlights: Science
• Over the past few years, we have funded research intended to identify surrogate endpoints for prostate cancer clinical trials so that the trials can be conducted more rapidly, with fewer patients, less expense and clearer results. This research has matured to the point that on June 21 and 22, the FDA convened a workshop attended by over 250 people to determine the optimal way to proceed. • We provided multiple research grants to Aaron Ciechanover, M.D., to support his investigation of the proteasome and possible applications to prostate cancer. For his groundbreaking work in this area, Dr. Ciechanover was awarded the 2004 Nobel Prize in Chemistry. Fund-raising
Publications The Prostate Cancer Foundation publishes many publications each year that highlight news and features about the Foundation’s support of prostate cancer research, programs, treatment projects, clinical trials, studies, resources and successful PCF partnerships.
Nobody Knows Few people realize that prostate cancer is the most common non-skin cancer in America, striking more than 230,000 men each year. The PCF has updated its informative booklet entitled Nobody Knows to raise prostate cancer awareness.
Board News Earle I. Mack Named Ambassador to the Republic of Finland President George W. Bush has confirmed Prostate Cancer Foundation board member Earle I. Mack to be Ambassador Extraordinary and Plenipotentiary of the United States of America to the Republic of Finland. Well-connected in both business and political circles, Mr. Mack has been a PCF board member since 2003, and was a senior partner and chief financial officer for the nearly century-old Mack Company. The firm, headquartered in Rochelle Park, New Jersey, invests, develops and manages income-producing commercial real estate. Mr. Mack has a long track record of success in business, and is a leading philanthropist supporting the arts, education and cancer research.
President George W. Bush has Report to the Nation The Report to the Nation on Prostate Cancer is a comprehensive overview of the stateof-the-art in the diagnosis, treatment and prevention of prostate cancer.
confirmed Prostate Cancer Foundation board member Earle I. Mack to be Ambassador Extraordinary and Plenipotentiary
We set records from our June fund-raising programs centered around
of the United States of America
to the Republic of Finland.
• Safeway once again demonstrated the strength of its commitment to the community by raising close to $3.4 million in its annual point-of-purchase program in all 1,800 Safeway, Vons, Pavilions, Dominick’s, Randalls, Tom Thumb, Genuardi’s and Carrs stores. • Our eighth annual Home Run Challenge in conjunction with Major League Baseball generated more than $2 million as hundreds of people around the country made donations. • Our newest program, the “Because You Love Him” eBay online auction, raised more than $200,000. More than 400 items were auctioned off, including lunch with pop star Avril Lavigne and dinner with Miss Universe 2004, Jennifer Hawkins, both of which sold for more than $16,000. The support from the eBay community of buyers and sellers was gratifying and established a solid foundation for dramatically expanding this program next year.
PCF NewsPulse The Prostate Cancer Foundation has launched NewsPulse, an email newsletter that educates individuals about the latest news and information regarding prostate cancer.
Visibility Although awareness alone will not result in better treatments for patients fighting prostate cancer, it helps to expand our donor base and harness more of society’s resources for this cause. Thus, we worked hard to get our message out.
• At our suggestion and with our support, NBC’s Today show featured prostate cancer as the health issue for an entire week. Public figures battling prostate cancer, including PCF chairman Mike Milken, Secretary of State Colin Powell, singer-actor Mandy Patinkin, retired U.S. Army general Norman Schwarzkopf and former New York mayor Rudy Giuliani, were interviewed, as were many of our most productive physician-scientists.
Annual Report The 2003 Annual Report summarizes the PCF’s accomplishments and focuses on the PCF’s pivotal role in research, the latest drugs in development and partnerships with major corporations like Safeway and AriZona Beverages.
We are proud of these accomplishments because we know that they hasten the day when prostate cancer will be merely a sad memory. As always, we appreciate your ongoing support. Very truly yours,
Leslie D. Michelson Vice Chairman and Chief Executive Officer
If you would like to sign up to receive these FREE publications, visit www.prostatecancerfoundation.org and enter the search word “PCF Publications” or contact us at 1.800.757.CURE.
At the 2001 New York Dinner, the PCF honored Earle Mack along with his brothers, David, Bill and Fred, for their widespread philanthropy that includes, in addition to support of the Prostate Cancer Foundation, major gifts to the Long Island Jewish Health System, whose North Shore University Hospital was ranked the number one hospital in the U.S. by the AARP. “I am grateful for the leadership and guidance Earle Mack has given the Prostate Cancer Foundation over the years. His contribution to the PCF will be missed and I wish him continued success in this next phase of his life as a public servant of the United States of America,” said PCF founder and chairman Mike Milken. Mr. Mack was sworn in as Ambassador to Finland on May 28, 2004.
FDA Holds First-Ever Workshop on Prostate Cancer Clinical Endpoints
PCF Launches Pharmaceutical Industry Roundtable
One of the main obstacles to making more prostate cancer treatments available to patients is the lack of accepted “clinical endpoints” for prostate cancer drug trials, other than patient survival. Currently, increased survival time is the key endpoint accepted by the FDA to prove the efficacy of a proposed prostate cancer drug. Because prostate cancer is slow-moving, this is an endpoint that takes years to reach, making drug development a very lengthy process. The FDA recognizes this problem and has been working to identify and obtain consensus on earlier markers.
Recognizing the vital role the pharmaceutical industry plays in the fight to find better treatments and a cure for recurrent prostate cancer, the Prostate Cancer Foundation has launched the Pharmaceutical Industry Roundtable. The Roundtable is designed to bring together many of the leading pharmaceutical and biotechnology companies committed to the development of effective therapies for prostate cancer. The PCF welcomes Abbott Laboratories, Aventis, Bristol-Myers Squibb, Novartis and Sanofi-Synthelabo as charter members of the Roundtable.
Because the Prostate Cancer Foundation is committed to clearing the path to better treatments and drugs for prostate cancer, the PCF has placed an extremely high priority on the development of new clinical endpoints that would expedite the testing and approval of new drugs. The PCF’s efforts include advocacy as well as research funding. The PCF is not alone in its desire to see the establishment of intermediate clinical endpoints and surrogate markers. In June, the FDA convened the first-ever “FDA Public Workshop on Clinical Trial Endpoints in Prostate Cancer” in Bethesda, Maryland. More than 250 people attended the workshop, which featured two days of presentations and panel discussions. Among the 19 speakers were PCF-funded researchers Anthony D’Amico, M.D., Ph.D., of the Dana-Farber Cancer Institute and Howard I. Scher, M.D., of Memorial Sloan-Kettering Cancer Center. PCF representatives at the workshop included Howard Soule, Ph.D., former executive vice president and chief science officer, and Gregg Britt, senior vice president, biopharmaceutical research and development. One of the main conclusions coming out of the presentations and discussion was that great potential exists to establish new “interim” clinical endpoints for prostate cancer drugs, allowing them to be approved on a conditional basis while the manufacturer continues with postapproval studies to evaluate the treatment against the gold-standard endpoint, increased survival time.
The goals of the Roundtable are to:
• Reduce barriers to the optimal treatment of prostate cancer.
Rather than relying on the results of a single test or marker as an interim endpoint, there was a great deal of discussion about the use of a composite endpoint. A composite endpoint would consist of two or more tests or markers that, when analyzed in tandem, proved to be a reliable indicator of the efficacy of a drug. While there was no clear consensus at the workshop on which single or composite endpoint was the best choice as an interim endpoint, there was broad agreement that development and acceptance of an interim endpoint was a necessary and crucial step in the effort to make more drugs and treatments available to prostate cancer patients. To that end, a follow-up working group meeting was convened in New York in August to establish more detailed recommendations regarding composite interim endpoints that could be used to help shorten the approval time for effective new therapies. The FDA is expected to deliver a detailed report on the workshop later this year to the Oncology Drugs Advisory Committee (ODAC), which reviews applications for cancer drug approvals and makes recommendations to the FDA. The PCF will continue to be an active participant in this vital effort.
• Promote and conduct prostate cancer research.
• Advocate for the accelerated approval of promising treatments that have been proven to be safe and effective in large clinical trials.
• Support development of assertive treatment guidelines and interdisciplinary medical education.
• Enhance awareness of prostate cancer and treatment options. The PCF gratefully acknowledges the support of the members of the Roundtable for providing underwriting for the PCF’s annual Scientific Retreat and for the recently released Report to the Nation on Prostate Cancer.
PCF Co-Sponsors Groundbreaking Prostate Cancer Symposium The Prostate Cancer Foundation announces its initiation and sponsorship of the 2005 Prostate Cancer Symposium, the first multidisciplinary symposium on prostate cancer with co-sponsorship from the American Society of Clinical Oncology (ASCO), the American Society for Therapeutic Radiology and Oncology (ASTRO) and the Society of Urologic
By convening the symposium, the sponsors are seeking to encourage more practitioners to take a multidisciplinary approach to prostate cancer treatment. Oncology (SUO). This conference will bring together for the first time leading urologists, oncologists and radiation therapists to discuss ways to accelerate research and improve care by increasing collaboration across specialties. The threeday symposium will be held February 17–19, 2005 at the Hyatt Grand Cypress in Orlando, Florida.
The 2005 Prostate Cancer Symposium will offer educational sessions and abstract presentations on prostate cancer prevention, screening, diagnosis, multidisciplinary treatment and translational research. The target audience for the symposium includes clinicians and researchers studying the biology, prevention, epidemiology, diagnosis and multidisciplinary treatment of prostate cancer. The organizers expect 500 or more attendees, including medical oncologists, urologists, radiation oncologists, radiologists, pathologists, epidemiologists, pharmacologists, pharmacists, translational-oriented laboratory scientists and nurses. By convening the symposium, the sponsors are seeking to encourage more practitioners to take a multidisciplinary approach to prostate cancer treatment, along the lines of the team approach taken by physicians treating breast, lung and other cancers. Among the topics that will be covered during the educational sessions will be reports on advances in multidisciplinary care of prostate cancer, including the optimal strategies for treating patients with prostate cancer. Continued on page 5
Prostate Cancer Glossary
It is important to learn some of the key terminology in the search for better treatments and a cure for recurrent prostate cancer. The following are two definitions you should know: Clinical Endpoint: In order for a new drug or treatment to be approved, researchers must show government regulators that it provides a measurable benefit to patients. The most logical way to do this is to measure the
improvement of the health or survival of patients following use of the experimental drug or treatment. This is the “clinical endpoint” of a drug trial. In prostate cancer, the most commonly accepted endpoint is an improved rate of patient survival, measured by the additional number of months or years added to the lives of the patients involved in the study. With a slow-progressing disease such as prostate cancer, it takes years to reach such a clinical endpoint, dramatically slowing the
search for new treatments. This is why researchers are hard at work to develop other accepted clinical endpoints that will more quickly measure the benefit patients receive from experimental treatments. Surrogate Marker: A surrogate marker is a clinical endpoint that proves the efficacy of a drug or treatment earlier because it reliably predicts a clinical endpoint, such as survival or measurable improvement in patient health. For instance, in prostate cancer, researchers are working hard to
find proven links between observed changes in PSA levels and survival. Such evidence would be considered a “surrogate marker” because changes in PSA levels are not direct evidence of improved patient health or survival but foreshadow it. If researchers can develop acceptable surrogate markers for prostate cancer research, it will dramatically reduce the time needed to develop new prostate cancer drugs and treatments.
n our last issue, Dr. Peter Gann, of Northwestern University, and Dr. Elizabeth A. Platz, of The Johns Hopkins Bloomberg School of Public Health, talked about research into nutrition, weight and prostate cancer care. We resume our Q&A to discuss other lifestyle factors and the future of prostate cancer research.
Q. We all know smoking is unhealthy, but is it considered a risk factor for prostate cancer? Dr. Gann: Most studies show no relationship insofar as risk is concerned, and in those that do show a risk it is very slight. We do not see the increased risk between smoking and prostate cancer that is present in lung cancer or heart disease. But while you can’t make the “no smoking” recommendation based on prostate cancer, we know that smoking is simply not a part of a healthy lifestyle. Dr. Platz: A person looking for reasons to quit, or better still, never to take up cigarettes at all, should know that tobacco use is implicated in numerous diseases. Lung, head and neck, bladder and pancreatic cancers, as well as cardiovascular disease, are among the many health risks associated with smoking. While there is no relationship between cigarette smoking and the incidence of prostate cancer, there are a number of studies that show a significant association between smoking and death from prostate cancer. We’ve also learned that a small number of those studies indicate that it is recent smoking history, rather than the cumulative effect of many years of tobacco use, that relates to death from the disease. Q. Does that mean we can tell men that quitting today can reduce their risk of dying from prostate cancer? Dr. Platz: Certainly, we hope so, but this has not been specifically studied. I can tell you I was involved with a retrospective study led by Dr. Patrick Walsh at Johns Hopkins—the surgeon who developed the nerve-sparing radical prostatectomy— to evaluate if cigarette smoking was associated with more aggressive disease, and we did find that smoking was associated with prostate cancer in which the tumor had already grown beyond the confines of the prostate.
Q. Is there a relationship between sexual activity and prostate cancer? Dr. Gann: This is not an easy thing to study for obvious reasons. At this point there are no plausible theories that suggest a relationship between frequency— or lack of frequency—of ejaculation and prostate cancer. There have also been studies examining sexually transmitted disease and prostate cancer and they did not demonstrate a connection. But, as I’m sure Elizabeth will mention because she is studying this, there is currently a lot of interest in the relationship between prostate cancer and inflammation of the prostate. This is interesting to us because inflammation causes the release of chemicals in the prostate that have the potential to damage DNA and potentially lead to development of cancer. Chronic inflammation of the prostate might well be caused by a microbial infection such as bacteria or viruses. Q. Are there factors being researched today that might have an impact on our understanding of recurrence of prostate cancer? Dr. Gann: Epidemiological studies have revealed interesting nutritional components from soy products that might prevent prostate cancer or slow progression of the disease. For example, one of those compounds, genistein, is a phytoestrogen —an estrogen-like compound in the soy plant. Estrogen is known to have some activity in the treatment of prostate cancer. Laboratory studies show that genistein appears to slow the progression of prostate cancer in experimental models. Let me add that while it is useful to
Dr. Platz: The Health Professionals Followup Study at Harvard now has a survival cohort where Dr. Ed Giovannucci and Dr. June Chan are investigating risk factors for prostate cancer progression as they study recurrence of the disease. The study, which has been partially funded by the PCF, has more than 3,000 men who have had a diagnosis of prostate cancer and are now being followed for outcome. Q. What are you working on right now? Dr. Gann: We’re about to begin a study on tomato extract that will enroll men at very high risk. These men have highgrade PIN (prostatic intra-epithelial neoplasia), a condition that is considered the premalignant precursor to prostate cancer. This study will look not at the occurrence of cancer, but at whether the tomato extract or placebo have different effects on the prostate tissue itself and whether those effects look as though they are protective or not. Q. Where do you see the future of the research that is going on today? Dr. Platz: Right now there is a strong focus on inflammation and prostate cancer—inflammation occurs when there are white blood cells moving into an area in response to infection or tissue damage. We are beginning to believe that this inflammation may increase the risk of prostate cancer.
Dr. Gann: Compared to 10 years ago, we have a lot of leads. What many of us are trying to do is tie together all this information so that we can create a coherent picture. As laboratory advances occur we want to get those results out into population studies as quickly as possible. The PCF ties into this because it is such a significant source of funding for research. As a private organization the PCF is in very close contact with the scientific community and is extremely responsive to suggestions and feedback. And I should add to the overall picture of the future, the increasing role of PSA screening, as well as the fact that just last year we had the first evidence from a randomized trial that a drug called finasteride can prevent prostate cancer. The results of the finasteride study showed a significant reduction in prostate cancer diagnosis in the group taking the drug for many years compared to those taking the placebo. Even with certain complexities of the results, finasteride is clearly a chemopreventive agent. Though I can’t speak for everyone, I don’t believe there is consensus as to who should be taking that drug. But it is so promising that there is no doubt that there will be new studies in the next few years better defining high-risk men who should consider finasteride to prevent the occurrence of prostate cancer.
Recommended online resources: Prostate Cancer Foundation www.prostatecancerfoundation.org American Cancer Society www.cancer.org National Cancer Institute www.nci.nih.gov Brady Urological Institute at Johns Hopkins www.urology.jhu.edu Miavita www.miavita.com
The Prostate Cancer Foundation Launches New Website
Q. What about alcohol consumption? Dr. Platz: The vast majority of the 60 or so studies on the subject say there is no association. But we took a look at patterns of alcohol consumption in the Health Professionals Follow-up Study and found that men who drank a large volume of alcohol over only one or two days of the week had a 60% higher risk of prostate cancer compared to men who drank less than one day per week or who did not drink at all. More research needs to be done in this important area.
pursue an understanding of individual compounds that may be beneficial, it is also vital to gain insight into the effects of the whole food, such as soy. After all, no individual compound found in soy, or any plant, operates in isolation. Plants have evolved over millions of years to develop compounds that interact with one another for biologic purposes. Therefore, the message I’d like to get across here is that eating the whole food gives you the benefit of the interaction of all the compounds.
ness and generate funds to accelerate research. In addition to serving as a resource for patients, the PCF will use the site to further simplify and accelerate how researchers can apply for funds, provide the media and others extensive information about prostate cancer and the PCF, and include information about our corporate partners and promotions. Some of the outstanding resources available to patients include: The Prostate Cancer Foundation has launched a new website to provide patients and loved ones comprehensive and easily accessible information about prostate cancer, treatment options, nutrition, lifestyle, risk factors and resources that can provide assistance. The PCF plans to use the site to help patients, raise aware-
• The Therapeutics Database, which catalogs all of the therapies under development for prostate cancer including a brief description of each. • The Prostate Cancer Foundation’s Monument Park, a memorial and tribute virtual park dedicated to people who have
been diagnosed with prostate cancer. On this page, you can honor that special person who has faced the challenge of prostate cancer. • The Report to the Nation on Prostate Cancer: You can download this 96-page report from the PCF’s home page.
Please visit the PCF website at www.prostatecancerfoundation.org and feel free to give comments or suggestions to the PCF webmaster at [email protected]
If you are interested in linking your site to the PCF website, please visit www.prostatecancerfoundation.org or email the communications department at [email protected]
The Connection The soybean was one of the sacred crops of
Besides using soy
the ancient Chinese emperors and it remains
sauce as a seasoning,
the highest-quality protein in the plant world.
what other ways are
Scientists have theorized that soy protein
there to increase your
may help reduce the risk of prostate, as well
soy intake? Here are
as other, cancers. In fact, the evidence is
significant enough that a petition for such a health claim has been submitted to the FDA.
• Use soy milk on your cereal or in your morning coffee or tea;
In addition to carbohydrates, protein and fat, soybeans contain isoflavones, which are believed to have anti-cancer properties. Japan, where soy protein intake is significantly higher than in the U.S., has a lower overall
• Have a soy protein shake for breakfast or lunch; • Substitute soy cheese for regular cheese;
and edamame (raw green soybeans)—
progressing cancers. Population studies find
where soy protein intake averages about 50
The steering committee for the symposium includes two members of the PCF’s Clinical Research Consortium: Eric Small, M.D., of the UCSF Comprehensive Cancer Center (chair of the symposium steering committee), and Kenneth J. Pienta, M.D., of the University of Michigan Medical Center. The PCF is represented on the program committee by Dr. Pienta as well as Maha Hussain, M.D., of the University of Michigan, Phillip Kantoff, M.D., of the Dana-Farber Cancer Institute (Boston, Massachusetts) and Matthew Smith, M.D., Ph.D., of Massachusetts General Hospital. Registration for the symposium is being handled through ASCO’s website at www.asco.org. For more information about the symposium, including additional sponsorship opportunities, contact Gregg Britt, senior vice president, biopharmaceutical research and development via email at [email protected]
• Try miso soup (made with soybean paste)
rate of prostate cancer as well as more slowly
a 34% decreased risk of cancer in countries
Prostate Cancer Symposium (cont. from page 3)
Did you know... • Prostate cancer is the most common
• Substitute marinated tofu for meat,
non-skin cancer in America, striking 230,000 men in 2003.
fish or chicken in traditional dishes; • As baby boomer men reach the target zone
grams per day. • Experiment with soy-based meat
for prostate cancer, beginning at age 50, the number of new cases is projected to
substitutes when preparing meals.
increase dramatically. By 2015, there will be more than 300,000 new prostate cancer cases each year, a 50% increase. • Every 18 minutes, a man dies from
Taste for Living
prostate cancer in the United States. • Compared to Caucasian men, African American men are 1.5 times more likely
As a recurring item in every newsletter, the Prostate Cancer Foundation includes a recipe from our cookbook encouraging you to change your diet without compromising your taste for living.
w Fruit Shake
Takes less than 30 minutes Makes one shake Ingredients 1/2 cup orange, pineapple, apple or mixed, unsweetened fruit juice 1/2 cup water 1/4 cup of frozen berries or frozen fruit of your choice 1 banana 2 scoops of strawberry or plain soy protein isolate powder
Preparation Place all ingredients in blender container and blend thoroughly. For extra cancer-fighting power, add: 1 teaspoon each of lemon and orange zest 3 capsules green tea powder (open capsules and use powder only) 1/2 cup brewed green tea instead of 1/2 cup water Nutritional Content Per serving: 265 Calories, 1.7g Fat, 0.2g Saturated Fat, 0g Cholesterol, 22.1g Protein, 42g Carbohydrate, 3.3g Fiber, 207mg Sodium Credits Recipe by celebrity chef Beth Ginsberg, co-author of the Taste for Living Cookbook. For more information, please contact the Prostate Cancer Foundation at 310.570.4700 or visit our website, www.prostatecancerfoundation.org.
to get prostate cancer and 2.3 times more likely to die from prostate cancer. • Prostate cancer has the strongest familial link of all major cancers. • Every 2 1/2 minutes a man is diagnosed with prostate cancer. • African American men have the highest incidence of prostate cancer in the world. • Your odds of making a hole-in-one are 1 in 38,000. Your odds of getting prostate cancer: 1 in 6. • A man is 33% more likely to get prostate cancer than a woman is to get breast cancer. • This year, 30,000 men will lose their lives to this deadly disease.
Is Your PSA Rising? Men who have been treated for prostate cancer and are still experiencing rising PSA may have hormone-resistant prostate cancer, an advanced form of the disease. Yet because of a lack of communication between their urologist and cancer specialists, they may not receive timely chemotherapy treatment. At this stage of disease, it is more important than ever for patients to involve a team of medical specialists—including a urologist, a medical oncologist and a radiation oncologist. The Prostate Cancer Foundation believes that a multidisciplinary approach to the management of prostate cancer results in optimal care because all therapeutic options can be offered to the patient.
In the ads, Arnie urges men with a rising PSA to “include an oncologist—a cancer specialist—in your treatment discussions. Talk with your urologist about including a medical oncologist on your healthcare team. The combined expertise of an urologist and an oncologist will help ensure you receive optimal care.” Arnie conducted a “satellite media tour” with news reporters at TV stations around the U.S. The Prostate Cancer Foundation would like to thank Arnold Palmer and Aventis, a member of the PCF Pharmaceutical Industry Roundtable, for supporting this campaign.
To address this issue and to help promote the concept of a multidisciplinary care team, the PCF rolled out a public service announcement starring Arnold Palmer that debuted in September during Prostate Cancer Awareness month.
Safeway Raises $3.4 Million for Prostate Cancer Research This June, Safeway, one of America’s premier food retailers, demonstrated its commitment to the communities it serves by once again conducting a successful campaign to raise awareness of, and funds for, prostate cancer research. Led by president and CEO Steve Burd, Safeway’s 200,000 employees in all 1,820 stores, including Carrs, Dominick’s, Genuardi’s, Randalls, Pavilions, Tom Thumb and Vons, used point-of-purchase promotions, candy sales, book sales, auctions and other creative means to raise close to $3.4 million for prostate cancer research. Since its inception in 2000, the program has generated more than $8 million for this vital cause. “We are in a race against time to find better treatments and a cure for prostate cancer,” said Leslie D. Michelson, vice chairman and CEO of the Prostate Cancer Foundation. “The strong and abiding support of Safeway and its customers will help us win that race.”
eBay “Because You Love Him” Auction Raises More Than $200,000 for the PCF There are many ways to support the work of the Prostate Cancer Foundation, including participating in the exciting “Because You Love Him” online auction. This summer, the Prostate Cancer Foundation teamed with eBay, The World’s Online Marketplace™, to auction more than 350 items, raising more than $200,000 for research to find better treatments and a cure for recurrent prostate cancer. The “Because You Love Him” auction was successful because generous donors provided scores of valuable auction items and thousands of people bid on them. Among the items auctioned to raise money for the PCF were dinner with Miss Universe 2004, Jennifer Hawkins; lunch with pop star Avril Lavigne; a private two-hour visit with former Los Angeles Laker Earvin “Magic” Johnson; an afternoon with golf legend Arnold Palmer; tennis with Donald Trump at his legendary Mar-a-Lago club in Palm Beach; a visit to the set of the hit TV show Las Vegas with star James Caan; lunch with legendary boxing promoter Don King; and dinner with world-renowned skateboarder Tony Hawk. Wish you would have had a chance to bid on these kinds of items? It’s too late for the 2004 auction, but be sure to check the PCF website next June, when we will announce the 2005 “Because You Love Him” online auction items and details. If you would like to donate an item for the auction, please contact PCF chief operating officer Debbie Bohnett at [email protected]
PCF Announces New Amateur Tennis Program The Pacific Life Open, an ATP Masters Series Event, has recently partnered with the Prostate Cancer Foundation to launch a new amateur doubles program, the Pacific Life Open Club Championships, to raise both awareness and funds for prostate cancer. As of October 2004, players from clubs across Southern California will compete in 40 qualifying amateur club tournaments for the right to advance and represent their tennis club at the Pacific Life Open Club Championships, scheduled to be held during the final weekend of the Pacific Life Open, March 18 – 20, 2005.
The tournaments are designed for men and women players who are members of a tennis club and have a maximum National Tennis Rating Program (NTRP) rating of 4.0. Players can sign up at their participating club as they would for any club-run or -sponsored event. An entry fee of $50 per participant ($100 per team) covers both qualifying competition as well as an all-expenses-covered weekend for each club champion at the Pacific Life Open Club Championships. Winning players from each club will receive gift certificates toward the purchase of tickets to the Pacific Life
New Yorkers Can Contribute to Prostate Cancer Research Through Tax Form Check-off On August 3, 2004, New York Governor George Pataki signed New York State Senate Bill 6206A providing for the new prostate cancer state tax check-off. Beginning with their 2004 tax returns, New Yorkers can now contribute to prostate cancer research by simply checking off a donation of any amount on their state tax returns. For every dollar contributed by the taxpayers, the State of New York and the Prostate Cancer Foundation have agreed to donate a dollar, so that every dollar donated becomes three dollars for prostate cancer research. The impetus for this bill began at the New York State Roundtable on Prostate Cancer, a meeting of the state’s leading cancer experts co-hosted by PCF founder and chairman Mike Milken and New York State Senate Majority Leader Joseph Bruno, both prostate cancer survivors. On the day of the signing, Senator Bruno said, “I thank Governor George Pataki and Assembly Speaker Sheldon Silver for partnering with the Senate on this critical legislation to unify and harness the efforts, energies and resources of the
Open, complimentary hotel rooms, invitations to both the Friday and Saturday evening cocktail and dinner parties, and credentials for the Pacific Life Open. In addition, all winners of the Pacific Life Open Club Championships will be recognized on Stadium Court following the Men’s Singles Final of the Pacific Life Open.
PCF Home Run Challenge 2004
on their state tax returns. These contributions will be placed in a 501(c)(3), the New York Coalition to Cure Prostate Cancer, which is dedicated solely to this cause. An independent panel comprised of the top prostate cancer research scientists will then distribute these funds through a competitive awards process to research centers throughout the State of New York conducting the most promising research to find better treatments and a cure for prostate cancer.
The Niebaum-Coppola Estate Winery in Napa Valley was the setting for the 12th anniversary of Cigar Aficionado’s “A Night to Remember.” In total, the evening raised close to $800,000 for
Cigar Aficionado editor and publisher Marvin R. Shanken and his wife, Hazel; former actress Janet Jones-Gretzky; Niebaum-Coppola winery owner Francis Ford Coppola; broadcaster Rush Limbaugh; Hall of Fame hockey legend Wayne Gretzky; and PCF chairman
returns, New Yorkers can now
off a donation of any amount
A Night to Remember
prostate cancer research. From left to right:
Beginning with their 2004 tax
research by simply checking
The PCF conducts and participates in many programs aimed at raising not only research funding but also public awareness of prostate cancer.
For more information, or to schedule a tournament at your club, please email tennis program coordinator Jessica Niebauer at [email protected]
medical and research communities and other organizations in an effort to help prevent prostate cancer and save lives. All New Yorkers owe a debt of gratitude to Mike Milken for his dedication and commitment to this effort.”
contribute to prostate cancer
Michael Milken. Dusty Baker, manager of the Chicago Cubs, joins fellow prostate cancer survivor and PCF chairman Mike Milken in donning blue wristbands in support of the 8th Annual Home Run Challenge. This game, between the Cubs and Astros, was held at Minute Maid Park in Houston, Texas, and was one of 60 designated games during Home Run Challenge week. When it comes to raising money to fight prostate cancer, the Prostate Cancer Foundation has been hitting them out of the park with the Home Run Challenge (HRC). Now in its eighth year, the PCF 2004 Home Run Challenge has teamed with Major League Baseball and the Major League Baseball Players Association in a nationwide slugfest that has raised more than $2 million to fund prostate cancer research. Baseball fans everywhere had the opportunity to pledge money for each home run hit in 60 preselected games beginning on June 11, and ending on Father’s Day, June 20. With 132 total home runs hit, this summer’s HRC sluggers have outdone themselves.
March 20–21, 2004— 3rd Annual Indian Wells Pro-Am Tennis Tournament Players from across the country paired together to help raise money in the fight against prostate cancer at the 3rd Annual Indian Wells Pro-Am Tennis Tournament. From left to right: Hall of Fame hockey legend and tournament champion Wayne Gretzky, businessman Dennis Washington, former number four world-ranked tennis player and tournament champion Jonas Bjorkman and PCF founder and chairman Mike Milken all participated in the Pro-Am Tennis Tournament.
Dave Perron, managing director of the HRC, still has the enthusiasm of a rookie who has been sent up to the Big Leagues.
PCF chairman Mike Milken (third from left) and PCF vice chairman and CEO Leslie D. Michelson (center) look on as New York Governor George E. Pataki (seated) signs into law legislation that will create a voluntary check-off box on New York State income tax forms. For every dollar contributed by the taxpayers, the State of New York and the Prostate Cancer Foundation have each agreed to donate a dollar, so that every dollar donated becomes three dollars for prostate cancer research.
“We have participation from every asset of the game, from management to labor—all the owners, the team executives, front office personnel, even the groundskeepers support our work. Every year this great effort is the result of the collaboration of several equally important elements: the number of donors we get, the level of participation from the general public, and of course, the number of home runs hit.”
Drive for the Cure John Nordstrom, actor Hal Linden and Stan Maron attended the PCF’s Drive for the Cure in Cabo San Lucas, Mexico.
Prostate Cancer Foundation • Funds innovative research that leads to better treatments. • Puts money in researchers’ hands quickly. • Brings together leading academic scientists with biotech and
pharmaceutical companies and government leaders and researchers. • Supports a consortium of the nation’s leading cancer centers. • Leads public awareness campaigns about prostate cancer. • Gives men and their families hope for better, longer lives.
Blue for Men
October ’04–January ’05 Pacific Life Open Club Championships Qualifying Tournaments
Major men’s fashion designers have joined the PCF to launch a nationwide, yearlong Blue for Men campaign to raise awareness and funds for prostate cancer research.
December 1, 2004 Survivor’s Celebration Breakfast Seattle, Washington December 1, 2004 Gourmet Games Los Angeles, California
Events 2005 February 25–27, 2005 The Carl H. Lindner Pro-Am Invitational The Mar-a-Lago Club Palm Beach, Florida
Board of Directors Michael Milken Chairman Prostate Cancer Foundation
Arthur Kern Chairman San Francisco Foundation
Elaine Wynn Co-Chief Executive Officer Wynn Resorts
Merv Adelson Chairman East West Venture Group
David Koch Executive Vice President Koch Industries
Jim Allchin Group Vice President, Platforms Microsoft Corporation
Shmuel Meitar Director Aurec Group
Stanley Zax Chairman and President Zenith National Insurance Corporation
James Blair General Partner Domain Associates
Lori Milken Vice President Prostate Cancer Foundation
Helene Brown Director, Community Applications of Research UCLA
Nelson Peltz Chairman and Chief Executive Officer Triarc Companies, Inc.
S. Ward (Trip) Casscells III, M.D. John Edward Tyson Distinguished Professor of Medicine and Vice President of Biotechnology University of Texas HSC, Houston
Lynda Resnick Vice Chairman Roll International
David Ederer Chairman Ederer Investment Company Sue Gin Chairman and Chief Executive Officer Flying Food Group, Inc. The Reverend Rosey Grier The Milken Family Foundation Andrew Grove Chairman Intel Corporation Stuart Holden, M.D. Director, Cedars-Sinai Louis Warschaw Prostate Cancer Center Warschaw, Robertson, Law Families Chair in Prostate Cancer Cedars-Sinai Medical Center
Robin Richards Chairman and CEO Notification Technologies Bert Roberts Consultant Richard Sandler Partner Maron and Sandler Executive Vice President The Milken Family Foundation Lorraine Spurge Managing Director Post Advisory Group Michael Tarnopol Vice Chairman Bear, Stearns & Co. Inc. Robert Voss President Fox Packaging Company Jerry Weintraub President Jerry Weintraub Productions
Executive Management Leslie D. Michelson Vice Chairman and Chief Executive Officer Ralph Finerman Secretary, Treasurer and Chief Financial Officer Debbie Bohnett Chief Operating Officer Stuart Holden, M.D. Medical Director Craig A. Dionne, Ph.D. Executive Vice President, Research and Therapeutics Gregg S. Britt Senior Vice President, Biopharmaceutical Research and Development Scott Harvey Senior Vice President, Corporate Alliances Jan Haber Vice President, Events and Donor Relations Helen Hsieh Vice President, Finance and Administration Martin Erck Vice President, Special Projects
For more information about these events, visit www.prostatecancerfoundation.org
One in six men will get prostate cancer. The PCF
provides funding for research to find the cure that will save lives. We provide hope to the men and families living with this disease. We must do more and we need your help to do it. Please return the enclosed pledge card today.
Nonprofit U.S. Postage PAID Los Angeles, CA Permit #33
1250 Fourth Street Santa Monica, CA 90401 Tel 310.570.4700 Fax 310.570.4701 www.prostatecancerfoundation.org